NEW YORK — March 3, 2026 — Leads & Copy — Lexeo Therapeutics, Inc. (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10 at 10:00 a.m. ET in Miami, FL.
The clinical-stage genetic medicine company, which focuses on developing novel treatments for cardiovascular diseases, will have the event webcast live on the company website’s investor relations page.
A replay of the webcast will be available on the Lexeo website following the presentation.
Lexeo is dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company is advancing a portfolio of therapeutic candidates that target the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Source: Lexeo Therapeutics, Inc.
